Aspirin-containing anti-brain stroke solid oral preparation

An oral preparation and aspirin technology, applied in the field of pharmaceutical preparations, can solve the problems of no aspirin stroke, no chlorzoxazone anti-stroke, etc., and achieve the effects of improving neurological deficits and preventing the expansion of infarct size.

Inactive Publication Date: 2015-05-13
THE FIRST AFFILIATED HOSPITAL OF XINXIANG MEDICAL UNIV
View PDF2 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

At present, there is no literature report on chlorzoxazone against stroke, and there is no literature report on its use in combination with aspirin for the treatment of progressive stroke

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Aspirin-containing anti-brain stroke solid oral preparation
  • Aspirin-containing anti-brain stroke solid oral preparation
  • Aspirin-containing anti-brain stroke solid oral preparation

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0016] Example 1: Clinical efficacy of aspirin combined with chlorzoxazone on progressive stroke

[0017] 82 cases of patients with progressive stroke. Inclusion criteria: ①Meet the diagnostic criteria adopted by the National Cerebrovascular Disease Academic Conference in 1995, and confirmed by cranial MRI as new cerebral infarction, excluding cerebral hemorrhage; ②Focal neurological function within 48 hours of onset Progressive aggravation of defect symptoms; ③No serious systemic complications; ④Those with bleeding history, peptic ulcer or blood system disease and those with bleeding tendencies are not eligible; ⑤Those with impaired consciousness are not eligible; Cannot be selected. According to the method of random grouping, all patients were randomly divided into the test group and the control group, with 41 cases in each group. The test group had 25 males and 16 females, with an average age of 69.5±8.2 years; the control group had 41 cases, 24 males, There were 17 female...

Embodiment 2

[0026] Example 2: Effect test of chlorzoxazone on simple right middle cerebral artery occlusion model

[0027] 40 SPF grade SD rats, male, body weight 200-240g. Rats were randomly divided into normal control group, model control group, low-dose and high-dose chlorzoxazone groups, with 8 rats in each group. After the test started, the low-dose and high-dose groups of chlorzoxazone were given 60 and 180 mg / kg of chlorzoxazone by intragastric administration respectively, and the normal control group and the model control group were given 10 mL / kg of normal saline by intragastric administration. Each group was administered once a day for 7 consecutive days. 3 hours after the last administration, except for the normal control group, the rats in other groups were established as follows in the simple right middle cerebral artery occlusion model (MCAO model): chloral hydrate 400mg / kg intraperitoneal injection of anesthetized rats, and then supine position Fix it on the operating tab...

Embodiment 3

[0028] Example 3: Preparation of compound aspirin enteric-coated tablets

[0029]

[0030] Preparation process: pass aspirin and chlorzoxazone through a 80-mesh sieve, and other excipients through a 100-mesh sieve, mix aspirin, chlorzoxazone, and mannitol according to the prescription ratio, add an appropriate amount of distilled water to granulate, and add carboxymethyl after drying Sodium starch glycolate and magnesium stearate are blended into granules, pressed into 1000 tablets, and then coated with enteric coating.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention discloses an anti-brain stroke solid oral preparation. The preparation comprises active ingredients and pharmaceutically acceptable auxiliary materials, wherein the active ingredients comprise aspirin and chlorzoxazone. The solid oral preparation can prevent enlargement of infarct size and has good curative effects of improving neurologic impairments of patients suffering from progressive stroke and restoring the activity of daily living, and severe adverse reactions are not caused in the treatment process.

Description

technical field [0001] The invention belongs to the technical field of pharmaceutical preparations, and relates to an anti-stroke solid oral preparation with aspirin as the main active ingredient. Background technique [0002] Stroke is the fourth leading cause of death in the world, second only to cardiovascular diseases, tumors and chronic lower respiratory diseases, and it is also one of the most important causes of lifelong disability. Among them, about 80% of the patients are ischemic strokes, the main cause of which is insufficient blood supply and oxygen supply to brain tissue caused by cerebral vascular obstruction or cerebral hemorrhage. It is predicted that the cost of stroke treatment in the United States from 2005 to 2050 will be about 152 billion U.S. dollars based on the purchasing power in 2005, which has caused a huge burden on the economy and health. In China, with economic development, changes in people's lifestyles and population aging, the incidence of s...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/616A61P9/10A61P25/28A61K31/423
Inventor 董亭方裴素娟牛晓露任瑞芳郗玉玲
Owner THE FIRST AFFILIATED HOSPITAL OF XINXIANG MEDICAL UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap